Scinai Immunotherapeutics (FRA:2F5) LT-Debt-to-Total-Asset: 0.18 (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Scinai Immunotherapeutics Ltd FRA:2F5

What is Scinai Immunotherapeutics LT-Debt-to-Total-Asset?

Scinai Immunotherapeutics FRA:2F5 -0.94% 20 LT-Debt-to-Total-Asset is 0.18 as of Mar. 2026. GuruFocus rates FRA:2F5 with a GF Score™ of 20/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Scinai Immunotherapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.18.

Scinai Immunotherapeutics's long-term debt to total assets ratio increased from Dec. 2024 (0.12) to Mar. 2026 (0.18). It may suggest that Scinai Immunotherapeutics is progressively becoming more dependent on debt to grow their business.

Scinai Immunotherapeutics (FRA:2F5) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Scinai Immunotherapeutics LT-Debt-to-Total-Asset Related Terms

Scinai Immunotherapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Scinai Immunotherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinai Immunotherapeutics LT-Debt-to-Total-Asset Chart

Scinai Immunotherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.89

0.78

1.15

0.12

0.17

Scinai Immunotherapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.00	0.16	0.17	0.18

20GF Score

Scinai Immunotherapeutics Ltd FRA:2F5

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Scinai Immunotherapeutics LT-Debt-to-Total-Asset Calculation

Scinai Immunotherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1.655	/	9.929
	=	0.17

Scinai Immunotherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	2.718	/	15.214
	=	0.18

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.18 mean?

Scinai Immunotherapeutics (FRA:2F5) has a LT-Debt-to-Total-Asset of 0.18 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Scinai Immunotherapeutics and its competitors.

Is Scinai Immunotherapeutics' LT-Debt-to-Total-Asset too high?

Scinai Immunotherapeutics' current LT-Debt-to-Total-Asset is 0.18. Overall, Scinai Immunotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.

How does Scinai Immunotherapeutics' LT-Debt-to-Total-Asset compare to ABPO and ISCO?

Scinai Immunotherapeutics' LT-Debt-to-Total-Asset of 0.18 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Scinai Immunotherapeutics and its competitors. Scinai Immunotherapeutics's current LT-Debt-to-Total-Asset is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Scinai Immunotherapeutics stock overvalued right now?

Scinai Immunotherapeutics (FRA:2F5) has a current LT-Debt-to-Total-Asset of 0.18. The current LT-Debt-to-Total-Asset is 0.18. Scinai Immunotherapeutics' overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Scinai Immunotherapeutics (FRA:2F5), the current LT-Debt-to-Total-Asset is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scinai Immunotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ABPO ISCO ZVSA AXIM EVFM HEPA LYRA CLSDQ BPTH ATXI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges SCNI:USA

Address Hadassah Ein Kerem Campus, 2nd Floor, Jerusalem BioPark, Jerusalem, ISR

Website https://www.scinai.com

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.

20GF Score

Get the complete analysis for FRA:2F5

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21

Price

View FRA:2F5 Analysis

See LT-Debt-to-Total-Asset data for all stocks →